Role of Human Papillomavirus Vaccines in Cervical and Vulvo-Vaginal Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Papillomavirus Vaccines".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 47
Special Issue Editor
Interests: gynecologic oncology; cervical cancer; preinvasive lesions; HPV vaccines
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The HPV vaccine has been established as the best option among prevention strategies to avoid the development of cervical cancer and other vulvar and vaginal diseases in women worldwide. During the last decade, we have observed a great evolution in HPV vaccines, such as the increase in HPV serotype coverage, a strategic implementation expanding to more age ranges, the inclusion of more targeted proteins, and other advances. Investigating the role of HPV vaccines may open a new horizon in the fight against cervical cancer, vulvar and vaginal cancer, and against preinvasive lesions. In addition, the current status of HPV vaccines, and the real coverage rates among different European countries, may give us an idea of the problem and a starting point from which we may get ahead.
All these topics make this Special Issue an opportunity to communicate promising research lines, new concepts, and results of immunization on different populations. We hope all authors and researchers consider this opportunity to publish their work in this Vaccines Special Issue.
Dr. Ignacio Zapardiel
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- human papillomavirus
- preinvasive lesions
- vulvar disease
- cervical intraepithelial neoplasia
- vaginal neoplasia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
